Valderilio Feijó Azevedo

Hospital de Clínicas Universidade Federal do Paraná

Valderilio Feijó Azevedo is an Associate Professor of Rheumatology and the former head of the Rheumatology Unit, Hospital de Clínicas, Federal University of Paraná (FPR), Brazil. Since 2009, he has been the owner and principal investigator of EDUMED Health Research and Education and EDUMED Biotech. His major research interests include clinical trials, regulatory advances in biologics therapies, spondyloarthritis, new treatment strategies for autoimmune diseases, biologics and biosimilars, and translational research in spondyloarthritis. Dr. Azevedo has authored several publications in the field. He is a member of the Brazilian Committee of Psoriatic Arthritis and coordinator of the Brazilian Committee of Biotechnology at the Brazilian Society of Rheumatology. He is also a member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), European Scleroderma Trials and Research (EUSTAR), and a former member of the Assessment of SpondyloArthritis international Society (ASAS). Dr. Azevedo is an executive board member of Americas Health Foundation, Washington, DC. He has worked on projects on pharmacovigilance of biologics and biosimilars and spondyloarthritis and has been the coordinator of the Latin American Forum on Biosimilars (FLAB) since 2010. He is also an advisory board member of the Alliance for Safe Biologic Medicines, Washington, DC.

Valderilio Feijó Azevedo

1books edited

1chapters authored

Latest work with IntechOpen by Valderilio Feijó Azevedo

Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versions of existing biological medicines and their active ingredients, are now available as more affordable options for patients treated with biologics. This book discusses biosimilars with chapters on clinical trials, regulation, pharmacovigilance, and the interchangeability of biosimilars with biologics. It also addresses future trends in the biosimilars market.

Go to the book
Biosimilars IntechOpen
Biosimilars Edited by Valderilio Feijó Azevedo


Edited by Valderilio Feijó Azevedo